Online inquiry

IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12882MR)

This product GTTS-WQ12882MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12882MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12073MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ2043MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AHLX-20
GTTS-WQ9427MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ5634MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ9463MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ9191MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ4654MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ9747MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW